Value: $2.9 billion
Scoop: In April, Endo Pharmaceuticals agreed to buy Minnetonka, Minnesota's American Medical Systems, a provider of devices and therapies for male and female pelvic health, for $30 per share, or about $2.9 billion in cash.
"This acquisition is a great step in achieving Endo's core strategy," Dave Holveck, president and CEO of Endo, said at the time. "Through the acquisition of AMS, we will gain scale in devices and services, and will be positioned as a leading provider of healthcare solutions in the field of pelvic health, with a full spectrum of product offerings ranging from pharmaceuticals to medical devices."
Although Endo had previously bought smaller urology-focused companies, Piper Jaffray analyst Thom Gunderson saw the AMS purchase as a major plus. "If you want to be in urology, you buy somebody like an American Medical Systems. They're renowned for their position in urology," he noted, as quoted by Minnesota Public Radio.
Morningstar's Debbie Wang said AMS has been a dominant force, especially in male pelvic health. "It's an area where they really do have a competitive advantage and they've consistently come up with innovation," she said, as quoted by MPR.